Akthelia Pharmaceuticals Announces Second Close of Follow-Up Pre-Seed Equity Round
Additional $200,000 new equity contributed to the round
REYKJAVIK, Iceland -- Jun, 29, 2022 -- Akthelia Pharmaceuticals announced today a second close to its earlier angel-led pre-seed follow-on funding round.
The second close of Akthelia's closed follow-up bridge funding round was twice oversubscribed. Akthelia will now continue laying the necessary groundwork pursue funding for pre-IND enabling and Phase 1 studies.
ABOUT AKTHELIA PHARMACEUTICALS
Akthelia Pharmaceuticals is a preclinical-stage biopharma company with a next-generation immunotherapeutic strategy to upregulate the innate immunology of epithelial surfaces. This novel approach has application potential to many areas of medicine and addresses the growing threat of antibiotic bacterial resistance (AMR) worldwide.
Akthelia’s lead therapeutic program upregulates the innate immunology in the GI tract, blocking leakage of microbiota to improve outcomes in cancer care through reducing the risk of neutropenia, a common and severe complication in chemotherapy and immunocompromised patients.
Egill Masson CEO email@example.com
Akthelia Pharmaceuticals Grandagarði 16 101 Reykjavik Iceland